单克隆B淋巴细胞增多症（MBL）的生物学前沿、进展及临床管理：血液癌症拦截研讨会委员会共识报告
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.
作者信息
Ryan Christine E, Ahn Inhye E, Sekar Aswin, Rawstron Andrew, Almeida Julia, Martin-Subero Iñaki, Parry Erin M, Alcoceba Miguel, Calado Dinis P, Orfao Alberto, Langerak Anton W, Veelken Hendrik, Langerbeins Petra, Stephens Deborah M, Parikh Sameer A, Niemann Carsten U, Roulland Sandrine, Stamatopoulos Kostas, Slager Susan L, Shanafelt Tait, Ghia Paolo, Okosun Jessica, Davids Matthew S
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
出版信息
Blood Cancer J. 2025 Aug 29;15(1):148. doi: 10.1038/s41408-025-01341-6.
In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.
2023年3月和2024年，一个国际专家小组在第一届和第二届拦截血癌（IBC）研讨会上召开会议，旨在更好地了解前驱恶性血液学疾病的诊断挑战、病理生理学以及潜在的治疗干预措施。在此，我们报告聚焦于单克隆B细胞淋巴细胞增多症（MBL）/慢性淋巴细胞白血病（CLL）的会议议程摘要。我们重点介绍四个主要内容领域：MBL的生物学特性、MBL的临床意义、MBL的进展以及惰性CLL向侵袭性疾病的转化，以及早期CLL的治疗干预机会。我们还概述了关键的共识管理建议和研究目标。
Zotero 插件